The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Edge Therapeutics Inc. netted $17.5mm through a registered direct offering of 1.8mm common shares at $10 (a 13% premium) to Satter Medical Technology Partners. The company will use the proceeds to further expand its pipeline and to fund pre-commercialization activities for lead compound EG1962, which is currently in Phase III for aneurysmal subarachnoid hemorrhage; results are expected later this year. EG1962 incorporates Edge's Precisa platform to create a polymer-based formulation of active ingredient nimodipine, delivered in a high concentration directly to the brain for sustained release in a single dose.

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $17.46mm
Transactions 1 of 1 (04/2017)
Equity $17.46mm
Total Line Value $17.46mm
Price/Share $10.00
# Shares 1.8mm
Shares Outstanding 30.81mm
Post-Money Valuation $308.11mm
Premium (Disc) as % 13%
Gross Proceeds $18.00mm
Net Proceeds $17.46mm
Investors Satter Investment Management LLC

Company Information

Click a keyword for comparable companies.

Edge Therapeutics Inc. | Ticker: EDGE
View Company Profile | View Company Deals
Company Location Worldwide
North America
Industry Biotechnology
Nanotechnology, Chips, etc.
Drug Delivery
Controlled Release
Site Specific
Ownership Public
Therapeutic Area(s) of Focus Blood & Coagulation Disorders & Products
Neurology, Nervous System
Company Advisors (Underwriters) Maxim Group LLC